Clinically relevant therapeutic endpoints in type I Gaucher disease

Journal of Inherited Metabolic Disease

Volumn 24, Issue SUPPL. 2, 2001, Pages 97-105

  Hollak, C E M ^a   Maas, M ^a   Aerts, J M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; BIOCHEMICAL MARKER; IMIGLUCERASE;

ARTICLE; BONE DISEASE; CONTROLLED STUDY; CYTOPENIA; DISEASE CLASSIFICATION; DRUG RESPONSE; ENZYME THERAPY; GAUCHER DISEASE; HEPATOSPLENOMEGALY; HUMAN; PRACTICE GUIDELINE; QUALITY OF LIFE; SUPPLEMENTATION;

BIOLOGICAL MARKERS; BONE DISEASES; ENDPOINT DETERMINATION; ENZYMES; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEPATOMEGALY; HUMANS; QUALITY OF LIFE; SPLENOMEGALY; TREATMENT OUTCOME;

EID: 0035152361     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012492429191     Document Type: Article

References (31)

1. Plasma and metabolic abnormalities in Gaucher's disease
2. Replacement therapy for inherited enzyme deficiency - Macrophage-targeted glucocerebrosidase for Gaucher's disease
3. The clinical course of treated and untreated Gaucher disease. A study of 45 patients
4. Gaucher disease
5. The human chitotriosidase gene. Nature of inherited enzyme deficiency
6. The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease
7. Gaucher disease: Recommendations on diagnosis, evaluation, and monitoring
8. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development
9. Gaucher's disease: Clinical features and natural history
10. Bone density at various sites for prediction of hip fractures
11. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: Results from a retrospective study
12. Quality of life in patients with Gaucher disease in the Netherlands
13. Effect of low-dose ERT on bones in Gaucher disease patients with severe skeletal involvement
14. A less costly regimen of alglucerase to treat Gaucher's disease
15. Current issues in enzyme therapy for Gaucher disease
16. Is there a correlation between degree of splenomegaly, symptoms and hypersplenism? A study of 218 patients with Gaucher disease
17. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease
18. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease
19. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy
20. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease
21. Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease
22. Radiological, biochemical and clinical parameters of skeletal disease in relation to fat fraction determination by QCSI in type 1 Gaucher disease
23. Quality of life assessment in adults with type 1 Gaucher disease
24. Analysis of the lipids of normal and Gaucher bone marrow
25. Current issues in diagnosis and treatment
26. Enzyme therapy in Gaucher disease type 1: Dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months
27. Risk factors for osteonecrosis in patients with type 1 Gaucher's disease
28. Accelerated skeletal deterioration after splenectomy in Gaucher type 1 disease
29. Enzyme replacement therapy for Gaucher disease: Skeletal responses to macrophage-targeted glucocerebrosidase
30. Determination of plasma chitotriosidase in Gaucher disease: Practical implications
31. Low-dose enzyme replacement therapy for Gaucher's disease: Effects of age, sex, genotype, and clinical features on response to treatment